Skip to main content
. Author manuscript; available in PMC: 2010 Sep 10.
Published in final edited form as: Mol Cancer Res. 2009 Mar 10;7(3):300–310. doi: 10.1158/1541-7786.MCR-08-0215

FIGURE 4.

FIGURE 4

Growth of K1735.hygro and K1735.Tie2Ex tumors. K1735.hygro and K1735.Tie2Ex tumors were created in C3H mice. A. Tumor-bearing mice were treated with or without doxycycline starting at 3 to 4 mm in tumor diameter for up to 3 wk. Growth of individual K1735.hygro and K1735.Tie2Ex tumors untreated (black line) or treated with doxycycline (gray line). B. Tumor-bearing mice were treated starting at 5 to 6 mm in tumor diameter for up to 3 wk. Growth of individual K1735.Tie2Ex tumors untreated (black lines) or treated with doxycycline (gray lines), treated with vehicle (black lines) or sorafenib (dotted lines), and treated with vehicle and doxycycline (solid gray lines) or sorafenib and doxycycline (dotted gray lines).